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A highly stable prefusion RSV F vaccine derived
from structural analysis of the fusion mechanism
Anders Krarup1,*, Daphné Truan1,*, Polina Furmanova-Hollenstein1,*, Lies Bogaert1, Pascale Bouchier1,
Ilona J.M. Bisschop1, Myra N. Widjojoatmodjo1, Roland Zahn1, Hanneke Schuitemaker1, Jason S. McLellan2
& Johannes P.M. Langedijk1

Respiratory syncytial virus (RSV) causes acute lower respiratory tract infections and is the
leading cause of infant hospitalizations. Recently, a promising vaccine antigen based on the
RSV fusion protein (RSV F) stabilized in the native prefusion conformation has been
described. Here we report alternative strategies to arrest RSV F in the prefusion conformation
based on the prevention of hinge movements in the ﬁrst refolding region and the elimination
of proteolytic exposure of the fusion peptide. A limited number of unique mutations are
identiﬁed that stabilize the prefusion conformation of RSV F and dramatically increase
expression levels. This highly stable prefusion RSV F elicits neutralizing antibodies in cotton
rats and induces complete protection against viral challenge. Moreover, the structural and
biochemical analysis of the prefusion variants suggests a function for p27, the excised
segment that precedes the fusion peptide in the polypeptide chain.

1 Janssen Infectious Diseases and Vaccines, Archimedesweg 4-6, Leiden 2333 CN, The Netherlands. 2 Department of Biochemistry, Geisel School of Medicine
at Dartmouth, Hanover, New Hampshire 03755-3844, USA. * These authors contributed equally to this work. Correspondence and requests for materials
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espiratory syncytial virus (RSV) is a highly contagious
childhood pathogen of the respiratory tract1. In children
younger than 2 years, RSV accounts for B50% of the
hospitalizations due to respiratory infections, with a peak of
hospitalization occurring at 2–4 months of age2. It has been
reported that almost all children have experienced infection with
RSV by the age of two3, and repeated infection during life is
attributed to low natural immunity. In the elderly, the RSV
disease burden is similar to those caused by non-pandemic
inﬂuenza A infections4.
A vaccine against RSV is currently not available, but is desired
due to the high disease burden. The RSV fusion glycoprotein
(RSV F) is an attractive vaccine antigen, since it is the principal
target of RSV neutralizing antibodies in human sera5–7. A
neutralizing monoclonal antibody against RSV F (palivizumab)
can prevent severe disease and has been approved for prophylaxis
in preterm infants8. RSV F fuses the viral and host cell
membranes by irreversible protein refolding from the labile
prefusion conformation to the stable postfusion conformation9.
Structures of both conformations have been determined for
RSV F10–13, as well as for the fusion proteins from related
paramyxoviruses, providing insight into the mechanism of this
complex fusion machine14–16. Like other class I fusion proteins,
the inactive precursor, RSV F0, requires cleavage during
intracellular maturation by a furin-like protease. RSV F
contains two furin sites, which leads to three polypeptides: F2,
p27 and F1, with the latter containing a hydrophobic fusion
peptide at its N terminus (Fig. 1)17,18. To refold from the
prefusion to the postfusion conformation, the refolding region 1
(RR1), which spans residues 137 through 216 and includes the
fusion peptide and heptad repeat A (HRA), has to transform from
an assembly of helices, loops and strands to a long continuous
helix (Fig. 2). The fusion peptide, located at the N-terminal
segment of RR1, is then able to extend away from the viral
membrane and insert into the membrane of the target cell. Next,
the refolding region 2 (RR2), which forms the C-terminal stem in
the prefusion F spike and includes the heptad repeat B (HRB),
relocates to the other side of the RSV F head. This allows HRB
to bind the HRA coiled-coil trimer and form the six-helix
bundle17,18. The formation of the RR1 coiled-coil and relocation
of RR2 to complete the six-helix bundle are the most dramatic
structural changes that occur during the refolding process.
Most in vitro RSV neutralizing antibodies in human sera are
directed against the prefusion conformation5, but due to its
instability the prefusion conformation has a propensity to
prematurely refold into the stable postfusion conformation,
both in solution and on the surface of the virions10,19. The
stabilization of the RSV F protein has recently been achieved by

the introduction of a disulphide bond between residues 155 and
290, introduction of two ‘cavity-ﬁlling’ substitutions at positions
190 and 207, and attachment of a heterologous trimerization
motif to the C terminus of HRB. These modiﬁcations led to the
generation of a stable prefusion molecule with modest expression
levels, but excellent immunogenicity in mice and macaques10.
An RSV F protein that has both high expression levels and
maintains a stable prefusion conformation would, therefore, be a
promising subunit vaccine candidate against RSV. Thus we
sought to identify novel stabilizing mutations based on an
understanding of the molecular basis of the prefusion instability
and refolding pathway. The high degree of disorder observed
previously in the HRA region, and especially in the apex of the
protein10,12, suggested that stabilization of this region might be
important to maintain the prefusion conformation. Therefore, we
focused on structure-based strategies to stabilize the apex by
preventing the refolding of RR1 by arresting the fusion peptide
and the hinging of a-helix 4. In addition, we sought to lock the
RR2 domain structure in place by reducing the charge repulsion
around the top of HRB, which is found at the bottom of the RSV
F head. These strategies led to the generation of a highly stable
prefusion RSV F that produced in high yields and protected
cotton rats against RSV challenge.
Results
Design of prefusion-stabilized RSV F. To stabilize the soluble
recombinant RSV F ectodomain, several RSV F variants were
designed with different modiﬁcations. To compensate for the loss
of the stabilizing transmembrane region, variants were designed
with a heterologous trimerization domain20, which proved
successful for PIV5 and RSV F10,11,16 (Supplementary Note 1).
To prevent the release of the fusion peptide, single-chain (SC)
variants were designed with a short linker between the F1 and F2
subunits of RSV F (Fig. 1). SC variants of the B1 strain with a
short linker showed higher expression levels and only the SC
variant combined with the ﬁbritin domain (SCB1) showed higher
expression levels and trimeric structure (Supplementary Table 1).
The same modiﬁcations in the background of the RSV F A2
(SCA2) also resulted in higher expression and trimerization
(Supplementary Table 1). However, over time the trimeric
protein gradually changed into the postfusion conformation as
determined by the loss of binding to the prefusion-speciﬁc
antibody CR9501 (ref. 21).
Stabilizing the a4–a5 hinge loop. To preserve the protein in the
prefusion conformation, we wanted to prevent the transition to
the postfusion conformation by stabilizing the regions between
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Figure 1 | Schematic representation of RSV F0 with refolding region 1 (RR1 in blue), refolding region 2 (RR2 in purple), p27 (yellow) and
remainder (green). F0 protein is cleaved at two positions (arrows) to generate F1 and F2. Upper sequence alignment shows design of single-chain (SC)
with short linker region (orange) compared with fragment of Fwt of strain A2 (subgroup A) and B1 (subgroup B). Lower sequence alignment shows
design of soluble truncated variant and variant with ﬁbritin domain (red) compared with fragment of Fwt of A2 and B1.
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Figure 2 | Strategy for prefusion F protein stabilization. RSV F trimer and magniﬁed views of prefusion F (left) and postfusion F protein (right)
indicating refolding region 1 (RR1, blue) and refolding region 2 (RR2, purple) and location of amino acid substitutions indicated by crossed circles.
The substitutions in the RR1 are designed to prevent the formation of the long helix. The substitutions in the RR2 are designed to reduce the negative
charge repulsion between the b23 strands.

the secondary structural elements that assembled into a long
coiled-coil during the transformation from pre- to postfusion
RSV F. In an attempt to stabilize the turns between a2–a3,
a3–b3, b3–b4 and a4–a5, proline residues were introduced
because of their restricted backbone dihedral angles (Fig. 2,
Supplementary Fig. 2). Of all single amino acid substitutions at
turns, substitution of position 161, 182 and 215 with proline
resulted in higher expression levels, and E161P and S215P also
increased protein stability (Fig. 3a,b). When the E161P or S215P
were introduced in a furin-processed (PR) version of RSV F
without the short loop, the expression of both increased more
than sixfold and at day 1 the amount of prefusion conformation
was B70% for PR-E161P and 100% for the PR-S215P variant
(Fig. 3a,b). To understand the strong stabilizing effect of S215P,
all 20 substitutions at position 215 were made and the variants
were tested for expression and stability of prefusion F protein.
As shown in Fig. 3c,d, only proline had a major impact on the
stability and expression whereas some medium-sized hydrophobic side chains had a minor effect.
Stabilizing a4 movement. A second strategy to stabilize
prefusion F protein was the restriction of the a4 movement. To
stabilize the apex and the disordered a4 helix and the b2–a1 loop,
the attachment of the b2–a1 loop to the three-helix bundle was
optimized (Fig. 2). Because a side chain at position 67 was the
most likely candidate to improve the interaction with the threehelix bundle, all substitutions at position 67 were made and the
variants were tested for expression and stability of prefusion F
protein. As shown in Fig. 3e,f, primarily hydrophobic residues
and particularly Ile, Leu and Met at position 67 were able to
increase expression and stability.
Reduction of charge repulsion in RR2. A third strategy to
stabilize prefusion F protein was the reduction of the negative
charge repulsion in RR2 due to clustered negative charges at the
top of the HRB. Therefore, an attempt was made to increase the
stability of the metastable SC variant by amino acid substitutions
of the negatively charged residues at positions 486 and 487

(Fig. 4a). Interestingly, none of the mutants showed a higher
prefusion stability beyond day 1 (data not shown), but most
showed higher expression levels in comparison to SC.
When the S215P and N67I substitutions were combined in a
single construct, a stable prefusion F protein was obtained that
had an eightfold higher expression level over the SC variant
(Fig. 4b,c). Addition of one of the substitutions at position 486 or
487 increased protein expression levels threefold more. In the
processed version of RSV F in which the fusion peptide is not
ﬁxed, the additive stabilizing effects of the individual mutations at
67 and 215 were substantial. The N67I substitution had the
strongest effect on both the expression level and stability but fully
stable prefusion F protein was obtained only when the 67 and 215
substitutions were combined, resulting in a 20-fold expression
level increase (Fig. 4d,e).
Biochemical evaluation of stabilized prefusion RSV F. To
characterize the prefusion RSV F protein, the double mutant SC
variant with the optimized apex (N67I, S215P: SC-DM) and the
triple mutant variant with the extra substitution that reduced
repulsion in the RR2 domain (N67I, S215P and E487Q: SC-TM)
were puriﬁed and analysed. The trimeric state of the puriﬁed
protein was conﬁrmed by SEC-MALS analysis and NativePAGE
(Supplementary Fig. 3a–c). The prefusion conformation was
conﬁrmed by ELISA (Supplementary Fig. 3d). Negative stain
electron microscopy (EM) was conducted on the protein to verify
the morphology. A two-dimensional class average showed a
compact trimer with a similar morphology to the typical diamond-shaped head of the recently crystallized prefusion RSV F
(Supplementary Fig. 3e)10,12. The heat stability of the puriﬁed
prefusion protein was determined by differential scanning
ﬂuorometry (DSF). Protein refolding from prefusion to
postfusion conformation detected using DSF occurred at 52.0
and 57.7 °C for SC-DM and SC-TM, respectively (Supplementary
Fig. 3f). Heated proteins no longer bound to the prefusionspeciﬁc Mab CR9501 but are still bound to CR9503 (data not
shown). Attempts to generate a soluble SC RSV F protein that
would include the p27 region by mutation of both furin cleavage
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sites did not result in detectable F protein (Supplementary
Table 1). To understand the impact of p27 on protein folding, a
single furin-site knockout was introduced in the native full-length
F protein and analysed for expression levels. Again, the furin-site
knockout variant showed little expression of F protein compared
with the normally processed full-length F protein (Fig. 5a).
Therefore, the furin-site knockout was introduced in a soluble F
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variant stabilized in the prefusion conformation that shows high
expression levels. Although the expression level of the furin-site
knockout variant was lower, a clear band for RSV F trimer could
be detected in NativePAGE (Fig. 5a). Despite the presence of the
ﬁbritin trimerization domain, over 6% of the protein that
contained the p27 peptide was monomeric, suggesting a
possible destabilizing effect of the p27 peptide on trimer
formation. Because the ﬁbritin motif in the soluble F protein
will drive the trimerization and NativePAGE conditions may not
be appropriate to evaluate the destabilizing effect of p27 on
trimerization, both proteins were subjected to denaturing
conditions to evaluate stability differences of quaternary
structure (Fig. 5b). Indeed, incubation with 0.1% SDS at room
temperature was able to monomerize 97% of the variant with the
attached p27 peptide despite the presence of the ﬁbritin domain,
while for the F protein without the p27 peptide, only 50% of the
trimer was monomerized suggesting a destabilizing effect of p27
on trimer formation.
Expression levels of SC-DM and SC-TM were compared with
DS-Cav1, a prefusion F protein stabilized by cavity-ﬁlling
mutations and a disulphide bridge10. As shown in Fig. 6, the
SC-TM variant expressed to almost three times higher levels and
both SC-DM and SC-TM remained stable in the culture
supernatants for 50 days, whereas DS-Cav1 gradually lost
prefusion conformation. Puriﬁed SC-TM has remained antigenically stable in the prefusion conformation at 4 °C for more
than 450 days based on binding to CR9501 (data not shown).

Crystallographic analysis. We determined the X-ray crystal
structures of two prefusion F variants with high expression levels
and stability to better understand the effect of these mutations on
the prefusion conformation (Fig. 4b-e). Structures of SC-TM
(N67I, S215P and E487Q) and the processed variant with the
optimized apex PR-DM (N67I, S215P) were determined to 2.4
and 2.3 Å, respectively (Table 1). The structures of SC-TM and
PR-DM were very similar to each other, with a root-mean-square
deviation of 0.40 Å for 445 Ca atoms (Supplementary Figs 4
and 6). In the SC-TM structure, electron density for parts of the
ﬂexible loop that connects F2 and F1 was observed within the
central cavity of the trimer. As the C terminus of F2 entered the
trimeric cavity, electron density became weaker, and linker
residues QARGSG could not be accurately placed due to the
disorder. After this gap, density became better ordered, allowing
linker residues in the turn (SGRS) to be accurately placed (Fig. 7).
In particular, the side chain of the Arg136 residue at the tip of the
loop was well ordered and occupied a pocket formed by residues
from its own protomer, as well as the fusion peptide of an
adjacent protomer. Overall, the conformation adopted by the turn
allowed residues in the fusion peptide to remain in the same
Figure 3 | Amino acid substitutions at positions 67 and 215 increase
expression level and prefusion stability of the F protein. (a,b) Protein
expression levels and prefusion stability of RSV F SCA2 variants and
processed variants (PRA2) with substitutions in RR1 (n ¼ 2–4). (c,d) Protein
expression levels and prefusion stability of RSV F SCA2 variants with all 20
amino acid substitutions at position 215 (n ¼ 1) and (e,f) at position 67
(n ¼ 2). Protein expression levels in cell culture supernatants were tested
72 h post transfection and fraction of RSV F protein binding to prefusion
speciﬁc CR9501 antibody on the day of harvest and after storage at 4 °C for
indicated period of time. (a,b,e and f)—bars represent average of 2–4
measurements, lines represent range of values; (c,d)—bars represent single
measurement. Amino acids are grouped according to physicochemical
characteristics (grey: hydrophobic, red: negative charge, blue: positive
charge). Variants in this and next ﬁgures are based on strain A2.
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exposed, unstructured region of the F2 subunit. Nevertheless, the
side chain of Ile67 points towards the interface of a1 and a4, and
packs against residues Leu83 and Val207 (Fig. 7). The third
stabilizing mutation, E487Q, which was only present in the SC
construct, does not result in a substantial change in side chain
conformation. However, conformational changes are observed for
Phe488 and Asp489, with the side chain of the former adopting a
different rotamer in the SC-TM structure. It is unclear as to
whether this conformational change is due to the E487Q
mutation or to the presence of the SC loop, which packs against
the alternate Phe488 side chain.
Both structures presented here were similar to DS-Cav1 (PDB
ID: 4MMU), with a root-mean-square deviation of 0.73 and
0.80 Å for PR-DM and SC-TM, respectively. The two regions that
differed the most from the DS-Cav1 structure included the loop
in F2 containing the N67I substitution and the loop in F1
between a4 and a5 containing the S215P substitution
(Supplementary Fig. 4). Thus, the N67I and S215P substitutions
preserved the overall conformation of the prefusion state and
only introduced small, local differences in two loops.
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Figure 4 | Amino acid substitutions have additive effect on RSV F protein
expression and stability. (a) Protein expression levels of RSV F SCA2
variants with substitutions at position 486 and 487. (b,c) Protein
expression levels and prefusion stability of RSV F SCA2 variants with
multiple substitutions. (d,e) Protein expression levels and prefusion stability
of processed RSV F PRA2 variants with multiple amino acid substitutions.
Protein expression levels in cell culture supernatants were tested 72 h post
transfection and fraction of RSV F protein binding to prefusion-speciﬁc
CR9501 antibody on the day of harvest and after storage at 4 °C for
indicated period of time. (a–c) n ¼ 3–4, Mean±s.e.; (d,e) bars represent
average of 2–4 measurements, lines represent range of values.

favourable conformations as those observed in the processed
structure (Supplementary Fig. 4).
In both structures the loop between a4 and a5, which includes
Pro215, is well ordered with the proline side chain pointing down
towards the interface of the triple helix formed by a1, a4 and a5,
and into a hydrophobic pocket formed by residues Val76, Ile79,
Ile206 and Thr219. The conformation of this region, however,
could be inﬂuenced by an adjacent trimer in the crystal lattice,
which packs head-to-head about the two-fold crystallographic
axis. The electron density for Ile67 is weaker than that observed
for Pro215, due in part to the intrinsic ﬂexibility of this solvent-

Immunogenicity and efﬁcacy of prefusion RSV F protein. To
evaluate the prefusion RSV F protein as a vaccine candidate, the
immunogenicity and protective efﬁcacy of the SC-DM protein was
evaluated in animal models and compared with that of postfusion
F protein. Mice were immunized intramuscularly with 0.5 mg of
RSV F at weeks 0, 4 and 8 with or without poly(I:C) as an adjuvant.
All mice generated antibody titers against the respective immunogen as measured by ELISA (data not shown). The prefusion
SC-DM construct induced signiﬁcantly higher virus neutralization
assay (VNA) titers against RSV A2 compared with postfusion
F protein. Furthermore, the adjuvanted prefusion F protein construct induced 10-fold higher neutralizing titers than the
adjuvanted postfusion RSV F construct (Supplementary Fig. 5a).
Because the cotton rat model is more permissive to RSV
infection than BALB/c mice, we chose this animal model for
challenge studies22,23. Cotton rats were immunized twice with 0.5
or 5 mg of either SC-DM prefusion or postfusion F proteins, both
without adjuvant or twice with SC-DM prefusion F protein in
combination with AdjuPhos (dosing at weeks 0 and 4). At week 7,
animals were bled and RSV neutralizing titers in serum were
determined. SC-DM induced a higher neutralization titer than the
postfusion RSV F protein against RSV A2, whereas the difference
for RSV Long was less pronounced likely due to overall low titers
against RSV Long. Addition of AdjuPhos signiﬁcantly enhanced
the neutralizing titers induced by the SC-DM prefusion F protein
(Fig. 8a,b).
Cotton rats were challenged intranasally with RSV Long at
week 7 and 5 days later RSV viral loads in the lungs and the nose
were measured. Immunization with 5 mg prefusion F protein
signiﬁcantly reduced the viral load compared with postfusion F
protein. Viral load on challenge was reduced to non-detectable
levels in the lungs of seven out of eight animals that had been
immunized with the prefusion F protein, whereas only one out of
eight animals receiving the postfusion F protein showed nondetectable viral load in this compartment (Fig. 8c). Protection
against challenge virus replication in the upper respiratory tract is
more difﬁcult to establish and was not achieved in animals
immunized with postfusion F protein, irrespective of the protein
dose. In contrast, animals that were immunized with 5 mg of
prefusion F protein showed a signiﬁcantly reduced viral load in
the nose compared with the postfusion F protein group (Fig. 8d).
The adjuvanted prefusion F protein at a dose of 5 mg gave
complete protection in lungs and nose, and even with 0.5 mg
of adjuvanted prefusion protein complete protection against
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Figure 5 | Inﬂuence of p27 on trimerization. (a, left panel) Full-length RSV F A2 and a variant mutated in one of the furin cleavage sites (F-DFurin: R135Q,
R136Q) were expressed in HEK293T cells and the puriﬁed membrane fractions were analysed by NativePAGE followed by Western blot to evaluate
expression and quaternary structure. (a, right panel) Soluble, stabilized processed F variant with ﬁbritin motif (PR-TM: N67I, S215P, D486N) and a furin site
cleavage mutant (PR-TM-DFurin) were analysed on NativePAGE followed by Western blot and (b) SDS–PAGE followed by Western blot. For SDS-PAGE,
samples were treated with standard 0.1% SDS buffer without reducing agents and without boiling. (bottom) Schematic representations of RSV F with
identical colour coding as Fig. 1 with additional transmembrane region (dark green) and ﬁbritin domain (red).
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Table 1 | Data collection and reﬁnement statistics.

1.5

Figure 6 | Comparison to DS-Cav1. (a) Protein expression levels for double
mutant single chain (SC-DM) and triple mutant single chain (SC-TM)
were compared with DS-Cav1 (ref. 10) in cell culture supernatants 72 h post
transfection and (b) the fraction of RSV F protein binding to prefusionspeciﬁc CR9501 antibody after storage at 4 °C for indicated days.
Bars or symbols represent average from two measurements, lines represent
range of values. On (b) prefusion F fraction at day of harvest (day 0) is
normalized to 1.

challenge virus was observed in the lung and in six out of eight
animals in the nose, indicative of a 10-fold dose sparing effect
for the adjuvanted protein. Furthermore, the sera showed
neutralization against a broad range of subtype A and B strains
(Supplementary Fig. 5b).

Reﬁnement
Resolution (Å)
No. of reﬂections
Rwork/Rfree (%)
No. of atoms
Protein
Ligand/ion
Water
B-factors
Protein
Ligand/ion
Water
r.m.s. deviations
Bond lengths (Å)
Bond angles (°)

3,517
35
161
56.3
58.4
46.8
0.003
0.70

3,459
66
173
56.1
105.7
48.0
0.005
0.86

PR-DM, furin-processed double mutant; r.m.s., root-mean-square deviation; SC-TM, triple
mutant single chain variant.

Discussion
The RSV F protein exists in a labile, high-energy state that refolds
irreversibly to drive membrane fusion. Because RSV F is the main
target of neutralizing antibodies, stabilization of the protein in the
high-energy prefusion conformation is required to obtain a
potent subunit immunogen5,10. To prevent the assembly of the
prefusion RR1 structural elements into one long coiled-coil as
happens on transition into the postfusion state, proline residues
were introduced in the loops and turns between the secondary
6

structure elements. Although a proline at position 161 and 182
did increase expression levels, only the S215P substitution in the
loop between a4 and a5 at the apex had a substantial stabilizing
effect. Helix a4 is the ﬁrst structural element that assembles on
top of the structurally conserved, preformed a5 helix base. The
ﬂexible a4–a5 loop must then be able to hinge around the nearby
conserved cysteine bridge (C69–C212). It is interesting to note
that S215P in the crystal structure has interaction with the top of
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Val207
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Lys80
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α1
α5
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Asp84
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Lys87

Single-chain

α5
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45°
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90°
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Figure 7 | Crystal structure of SC-TM. The trimer is displayed with two protomers as white and grey molecular surfaces and the third protomer as a
green ribbon. RR1 with its N-terminal FP is dark blue, and RR2 is dark purple. The stabilizing mutations (Ile67, Pro215 and Gln487) are coloured red (except
in the lower right panel), and the loop connecting F1 and F2 is orange. Each of the smaller panels depicts a magniﬁed view of one of the four stabilizing
strategies, and their orientation with respect to the main panel is indicated. The lower left panel shows a slice through the trimer, and the dashed orange
line represents the disordered portion of the loop. In the lower right panel, hydrogen bonds are depicted as black dotted lines.

the hydrophobic core formed by helices a1, a4 and a5 at the apex
of the protein. When compared with other hydrophobic
substitutions at this position, only proline has a strong effect
(Fig. 3c,d). Because the hydrophobic residues isoleucine and
valine show only a partial stabilizing effect and lower expression,
a proline at position 215 has additional beneﬁts and may prevent
hinging of a4 by both rigidifying the ﬂexible turn and locking the
a4–a5 loop to the hydrophobic core. We note that the S215P in
the a4–a5 hinge loop is at a structurally equivalent position as the
HIV-1 I559P, which is the most successful mutation to stabilize
the HIV-1 trimeric prefusion structure24. These equivalent
stabilizing mutations suggest that a common early triggering
event could exist for class I viral fusion proteins.
The different conformations adopted by the disordered b2–a1
loop and its variable interaction with a1 and a4 (refs 10,12,13,25)
suggest that the b2–a1 loop could inﬂuence the movement of a4.
Thus, improving the interaction with a1 and a4 could stabilize
the apex region. Residue 67 in the b2–a1 loop was selected
for site-directed mutagenesis because it is most likely less
antigenically important than the charged residues at position
65, 66 and 68 and because if all prefusion RSV F structures are
compared, the Asn67 side chain does not have a ﬁxed position
and is able to reach helix a1 and a4 that form a three-helix
bundle with a5. Our results showed that indeed hydrophobic
residues and especially isoleucine increased expression levels and
had a dramatic impact on the stability by hydrophobic interaction
with a1–a4 (Fig. 3e,f). The mutations at position 67 and 215 in
the b2–a1 loop and the a4–a5 loop, respectively, provide two
independent remedies to prevent helix a4 from moving and
hinging. The combination of substitutions N67I and S215P
showed a clear additive effect on expression levels and also on
stability of prefusion F protein. The high expression and
prefusion stability agree with proper folding that has passed
cellular quality control.

Although the apex showed the highest level of disorder in
previous prefusion RSV F crystal structures10, the bottom of
the RSV F head is also an area of instability. In this study we tried
to stabilize the bottom of the head by reducing the negative
charge repulsion at the interface between the protomers. None of
the substitutions at position 486 and 487 had a strong stabilizing
effect on the semi-stable SC protein but when they were
applied to the RSV F variant with the stabilized apex (SC-DM)
the mutations at the bottom did show an effect on both heat
stability and expression levels (Fig. 4 and Supplementary Fig. 3f).
The E487Q substitution reduced the negative charge repulsion
and the glutamine could hydrogen bond across the trimer
with D486 from another protomer (Fig. 7). Most likely, D486N
has a similar structural effect. A previous attempt to increase
prefusion F protein stability by neutralizing the negative
patch was not successful10. All three negative charges were
substituted (D486H-E487Q-D489H), resulting in lower yields
and a tendency to aggregate along with sensitivity to low pH
(ref. 10). This more substantial change would not allow the
hydrogen bond network observed with the single E487Q
substitution, and the six clustered histidines could cause charge
repulsion at low pH.
Exploration of the stabilizing strategies for RSV F and
crystallographic analysis of the prefusion RSV F proteins offers
a putative mechanism of protein refolding from the pre- to
postfusion conformation. It is interesting to note that none of the
other proline substitutions at the various RR1 hinge points had a
stabilizing effect except for the S215P substitution in the a4–a5
loop, which is at the opposite end of the RR1 domain compared
with the fusion peptide. Even substitution E161P that was
designed to prevent the helix formation by stabilizing the turn
and reducing the negative charge repulsion hardly had any
stabilizing effect. Another interesting structural observation on
HRA is seen in the crystal structure of RSV F containing an
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introduced disulphide bond between residues 155 and 290 (PDB
ID: 4MMQ)10. In this structure, a large part of the RR1 region is
disordered, although the fusion peptide is ﬁxed in its position by
the introduced disulphide bridge that connects it to the b2 strand.
This suggests that the release of the fusion peptide from inside the
cavity is not required for RR1 refolding and can occur at a later
stage. Therefore, the release of the fusion peptide could be
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triggered by an event (like receptor binding) at the apex that
results in the release of a4 and concomitant hinge motion in the
a4–a5 loop. This critical hinge will pull on RR1 and eventually
pull the fusion peptide from its position like the hinging of a
shoulder joint could liberate a hand from a pocket without relying
on a movement from the elbow or wrist (Fig. 9).
The X-ray structure of the single chain SC-TM showed that
the structure was very similar to processed prefusion structures
(Supplementary Fig. 4). Hence, even connected with a linker, the
fusion peptide and the C terminus of F2 are located inside
the hollow void of the F trimer. Still unknown is how this looped
b-hairpin of fusion peptide and C terminus of F2 ended up there.
It either tunnelled in through the small pore on the side of the
trimer (Figs 7 and 9) or the loop was already there before the pore
formed. The largest diameter measured in the pore is about 13 Å,
which would be too small to consider the entrance of a tight
b-hairpin (fusion peptide and C terminus of F2). Therefore,
the observation that the b-hairpin of fusion peptide and
the C terminus of F2 is located in the cavity might hint to a
state where the fusion peptide and the F2 C terminus were
already folded in their current position in monomeric F protein
because the b-hairpin is too bulky to tunnel into the interior via
the pore of trimeric F protein. Consequently, if this would also
apply for wild-type RSV F, the presence of the bulky p27 domain
in the folded unprocessed monomer would obstruct full trimer
formation. It is only after cleavage that the monomers can
assemble and form an unstable native trimer with a trapped F2 C
terminus and a fusion peptide that provides some stability at the
bottom of the head by hydrophobic interactions with b-sheet 3, a
neighbouring fusion peptide and the walls of the cavity. When
RSV F variants were compared, it was shown that F variants that
could not be processed by furin and still contained the p27
peptide were hardly expressed and it was indeed shown that
the p27 peptide had a negative impact on trimerization even
when a trimerization motif was present (Fig. 5). Trimerization
after cleavage is new in the RSV ﬁeld, and may also be unique to
RSV F since uncleaved ﬂu HA, PIV5 F and HIV-1 Env have all
been shown to exist in trimeric conformations that are very
similar to the cleaved protein. The trimerization of RSV F
also brings some inherent instability exempliﬁed by the
unfavourable b-bulge in b23 and alignment of a series of negative
charges in a repulsive ring around the three-fold axis which
causes electrostatic repulsion at the trimer interface (Figs 2
and 9). Therefore, when the fusion peptide is released from the
cavity after RR1 C-terminal refolding, the stabilization by
hydrophobic interactions will vanish and the repulsion at the
trimer interface will prevail and trigger the refolding of the RR2
domain (Fig. 9).
The structural insights and stabilization strategies presented
here produced a prefusion RSV F protein that was stable on
Figure 8 | Prefusion RSV F protein is immunogenic and protective in
Cotton rats. Female Cotton rats (n ¼ 8 per group) were immunized IM with
0.5 or 5 mg stabilized prefusion RSV F protein (SC-DM) or RSV F protein in
postfusion conformation in a prime—boost regimen at week 0 and week 4.
SC-DM groups at the same protein doses was further combined with
AdjuPhos. Serum was collected on day 49 and plaque reduction assay was
performed using (a) RSV A2 and (b) Long as described in Materials and
Methods. RSV virus titer was determined in (c) the lungs or (d) nose tissue
homogenates of cotton rats at day 5 after challenge (day 54 after prime
immunization) as determined by plaque forming units per gram of tissue.
Horizontal lines indicate medians. Limit of detection is shown as dotted line.
Groups were statistically compared using a non-parametric CochranMantel-Haenszel test. Comparisons across doses are indicated by
horizontal lines above the 0.5 and 5 mg groups. Signiﬁcance was accepted at
the Po0.05 level and P-values below 0.05 are indicated in the ﬁgure.
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a
RSV F is expressed as a monomer.
Cleavage allows trimerization.

Hydrophobic forces
drive trimerization.

Hydrophobic interactions lock
the prefusion conformation.

RR1
Furin cleavage site
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RR2

b

RR1 unfolding is initiated at the apex
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in the upper part of the HRB.

Release of the fusion peptide
triggers the RR2 unfolding.

Formation of the six helix bundle
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Figure 9 | Schematic representation describing how cleavage can activate trimerization and how trimerization causes an inherent instability in the
RR2. (a) Trimerization of monomeric RSV F is obstructed by the uncleaved bulky glycosylated p27 region. Cleavage of F0 allows trimerization and
hydrophobic interaction of the fusion peptide with adjacent protomer. (b) The trimerization creates an unstable area in the RR2 through the alignment of a
repulsive ring of negative charges contributed by residues Asp486 and Glu487 that are located on b23 that contains an unstable b-bulge (at the edge
of b-sheet 3, Fig. 2). The repulsive electrostatic and static forces are countered by the hydrophobic forces linking the FP to the bottom of the cavity.
After RR1 is triggered to refold by an unknown mechanism at the apex, it pulls away the stabilizing hydrophobic FP from the cavity which will destabilize the
repulsive ring. This results in release of RR2 and ultimately binding of HRB to the HRA coiled-coil to form a 6-helix bundle that is characteristic of the
postfusion conformation.

storage at 4 °C for more than a year and was also heat
stable (Supplementary Fig. 3), which is an important requirement
for vaccine development. As expected from a stabilized prefusion
RSV F protein, higher titers of neutralizing antibodies were
induced in rodents compared with postfusion RSV F. Especially
the efﬁcacy of the prefusion protein to protect cotton rats against
replication of RSV challenge virus in the nose was signiﬁcantly
higher than the efﬁcacy of the postfusion F. Even a prime boost
with non-adjuvanted prefusion protein almost completely
protected against RSV replication in the nose. With AdjuPhos
as adjuvant protection could be reached with a prime boost of
0.5 mg of prefusion protein.
In conclusion, with a minimal number of unique amino acid
substitutions focused on stabilization of helix a4 in the disordered
apex, a stable prefusion RSV F protein was constructed that could
be produced to high yield in mammalian cells. Prefusion RSV F
elicited broadly neutralizing antibodies and induced full protection against viral challenge in cotton rats. Protein engineering for
vaccine development has led to a stabilization strategy that has
brought new insights in the unique role of the enigmatic p27
peptide in RSV F function and additional broader insights in
triggering events in class I viral fusion proteins.

Methods
Ethics statement. This study was carried out in strict accordance with the
recommendations in the Institutional Animal Care and Use Committee guidelines
for cotton rat studies. Studies in mice were performed according to Dutch law
(Dutch Animal Experimentation Act) and Guidelines on the Protection of
Experimental Animals by the Council of the European Committee (EU
Dir. 86/609) after approval by the Dier Experimenten Commissie (permit number
21300). All invasive procedures were performed under isoﬂuorane anaesthesia, and
all efforts were made to minimize animal suffering.
Viruses and cells. The following RSV strains were used: A2 (ATCC, VR1540),
Long (ATCC, VR-26), B1 (ATCC, VR2542 ), RSV 05-036549 (kindly provided by
Dr F. Coenjaerts, Utrecht Medical Centre, Utrecht, The Netherlands), RSV A CL57,
RSV A CL25, RSV B 423, RSV B CL19 (kindly provided by Dr D. Roymans,
Janssen Pharmaceuticals, Beerse, Belgium) and RSV B15/97 (kindly provided by
Sigmovir Biosystems, USA). Large-scale RSV preparations were produced by
infecting Hep2 cells (ATCC, CCL-23), and harvesting the cell culture supernatants
3–4 days after infection. Cell culture supernatants were stabilized in 25% sucrose in
phosphate-buffered saline (PBS) and stored at  80 °C.
Expression and puriﬁcation of antibodies and Fab fragments. Fully human
IgG1 anti-RSV F protein antibodies CR9501, CR9503, CR9515 and CR13039 were
constructed by cloning the heavy (VH) and light (VL) chain variable regions into a
single IgG1 expression vector. PER.C6 cells (Crucell) were transfected with the
IgG1 expression constructs and the expressed antibodies were puriﬁed from culture
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supernatants using POROS Mabcapture A chromatography (Applied Biosystems)
and then buffer exchanged to 50 mM NaAc, 50 mM NaCl, pH 5.5. Antibody
concentration was measured by optical absorption at 280 nm. Antibody quality
was also conﬁrmed by size-exclusion chromatography (SEC), SDS–PAGE and
isoelectric focusing. CR9501 comprises VH and VL regions of 58C5, which binds
speciﬁcally to RSV F protein in its prefusion conformation and not to the postfusion conformation21. CR9503 comprises VH and VL regions of motavizumab26.
CR9515 comprises VH and VL regions of D25 antibody27. CR13039 comprises VH
and VL regions of MPE8 antibody28.
Expression and puriﬁcation of RSV F protein. Expression plasmids encoding
the recombinant prefusion RSV F protein were generated as follows. Parental
construct based on RSV A2 (Genbank ACO83301.1) was ordered from GeneArt
(Life Technologies). It consists of residues 1–513 of the F protein and ﬁbritin
trimerization domain. Amino acid substitutions were introduced by site-directed
mutagenesis (QuickChange II Site-Directed Mutagenesis kit, Agilen Biotechnologies). For RSV F in postfusion conformation a DNA construct encoding RSV F
residues 1–136 and 146–524 (corresponding to the F protein ectodomain without
the fusion peptide)13 was synthesized (GeneArt). Recombinant proteins were
expressed in 293 Freestyle cells (Life Technologies). The cells were transiently
transfected using 293Fectin (Life Technologies) according to the manufacturer’s
instructions and cultured in a shaking incubator at 37 °C and 10% CO2. The
culture supernatants containing F protein were harvested on 5th day after
transfection. Sterile-ﬁltered supernatants were stored at 4 °C until use. The
recombinant polypeptides were puriﬁed by a two-step protocol applying a cation
exchange chromatography followed by SEC. For the ion-exchange step the culture
supernatant was diluted with two volumes of 50 mM NaOAc, pH 5.0, and passed
over a 5 ml HiTrap Capto S (GE Healthcare) column at 5 ml min  1. Subsequently
the column was washed with 10 column volumes of 20 mM NaOAc, 50 mM NaCl,
0.01% (v/v) Tween20, pH 5, and eluted with 2 column volume of 20 mM NaOAc,
1 M NaCl, 0.01% (v/v) Tween20, pH 5. The eluate was concentrated and the
protein was further puriﬁed on a Superdex200 column (GE Healthcare) using
40 mM Tris buffer, 500 mM NaCl, 0.01% (v/v) Tween20, and pH 7.4 as running
buffer. A reduced SDS–PAGE analysis was used to determine purity of the ﬁnal
protein preparation; only protein with purity 495% was used for further analysis.
The identity of the band was veriﬁed using western blot with CR9503.
SDS–PAGE analysis and western blot. Cell culture supernatants or puriﬁed
protein samples were analysed on 4–12% (w/v) Bis–Tris NuPAGE gels, 1  MOPS
(Life Technologies) under reducing or non-reducing conditions and blotted using
the iBlot technology (Life Technologies). All procedures were performed according
to manufacturer’s instructions. For purity analysis the gels were stained with
Krypton Infrared Protein Stain (Thermo Scientiﬁc) or SYPRO Rubi protein stain
(Bio-Rad). The blots were probed with CR9503 at 1 mg ml  1, followed by
IRDye800CW conjugated anti-human IgG (rabbit; Rockland Immunochemicals,
Gilbertsville, PA, USA). The gels and the blot membranes were scanned on an
Odyssey instrument (Li-Cor) and images analysed using Odyssey 3.0 software
(Li-Cor).
Conﬁrmation of trimeric state. Multimeric state of the prefusion RSV F protein,
puriﬁed or in crude cell culture supernatant, was analysed in a NativePAGE
Bis–Tris gel system (Life Technologies). For conﬁrmation of the bands identity and
for analysis of proteins in crude cell culture supernatants, the gels were blotted as
described above. The gels and the blots were analysed on Odyssey instrument as
described above. Size of the proteins was estimated in comparison with a Native
Standard (NativeMark, Life Technologies).
RSV F protein was monitored by SEC and multi-angle light scattering analysis
using a high-performance liquid chromatography system (Agilent Technologies)
and miniDAWN TREOS (Wyatt) instrument coupled to a Optilab T-rEX
Refractive Index Detector (Wyatt). In total, 40 mg of protein was applied to a
TSK-Gel G3000SWxl column (Tosoh Bioscience) equilibrated in running buffer
(150 mM NaPi, 50 mM NaCl, pH 7.0). The data were analysed by the Astra 6
software package and molecular weight calculations were derived from the
refractive index signal.
Quantitative octet assay. To measure the concentration of the prefusion RSV F
protein in cell culture supernatants, a quantitative Octet-based method was used.
The CR9501 and CR9503 antibodies were biotinylated and immobilized at
5 mg ml  1 on Streptavidin biosensors (Pall). The antibody-coated biosensors were
blocked in mock cell culture supernatant. Quantitative experiment was performed
on an OctetRED384 instrument (Pall) at 30 °C shaking speed 1,000 r.p.m. for 300 s.
Concentration of the protein was calculated using standard curves, which were
prepared for each coated antibody using the SCDM protein, diluted in mock cell
culture supernatant. The data analysis was performed using the ForteBio Data
Analysis 6.4 software (ForteBio). Negative control samples (mock cell culture
supernatants) were used for reference subtraction. The algorithm used was
‘Linear point-to-point’.
10

Stability studies. Ability of the prefusion protein to spontaneously convert into
postfusion conformation was assessed in a storage stability assay. The crude cell
culture supernatant samples were stored at 4 °C and concentration of the F protein
in the samples was measured on Octet instrument by quantitative assay as
described above. The measurement was done on the day of supernatant harvest
(day 1) and after storage for indicated period of time. CR9503 was used to measure
the total F protein concentration; CR9501 was used to measure prefusion RSV F
protein concentration.
Temperature stability of the puriﬁed proteins was determined by DSF. The
puriﬁed prefusion F protein was mixed with SYPRO orange ﬂuorescent dye
(Life Technologies S6650) in a 96-well optical quantitative PCR plate. The optimal
dye and protein concentration was determined experimentally (data not shown).
All protein dilutions were performed in PBS, and a negative control sample
containing the dye only was used as a reference subtraction. The measurement was
performed in a quantitative PCR instrument (Applied Biosystems ViiA 7) using the
following parameters: a temperature ramp from 25 to 95 °C with a rate of
0.015 °C sec  1. Data were collected continuously. The melting curves were plotted
using GraphPad PRISM software (version 5.04). Melting temperatures were
calculated at the 50% maximum of ﬂuorescence using a non-linear EC50 shift
equation.
ELISA. Binding of the prefusion RSV F proteins to prefusion-speciﬁc neutralizing
antibodies was tested in an ELISA. The MaxiSorp polystyrene 96-well plates
(NUNC) were coated with anti-RSV F monoclonal antibody (MAB8262, Millipore)
over-night at 4 °C in PBS. The antibodies were diluted in PBS at 1 mg ml  1. The
next day, plates were washed with washing buffer (PBS, 0.05% Tween) and blocked
in PBS with 1% bovine serum albmin. All incubations were performed at room
temperature for 1 h. After each step, plates were washed three times with the Wash
buffer. Titrations of the puriﬁed RSV F protein were prepared in the washing buffer
with 1% bovine serum albmin. Test antibodies were biotinylated according to
standard procedure and diluted in the same buffer at 0.25 mg ml  1. For detection,
Streptavidin-HRP (BD Bioscience) was used at 1:1,000 dilution with a TMB
Microwell Peroxidase Substrate System (KLP).
Electron microscopy. Electron microscopy studies were performed by
NanoImaging Services, Inc. (CA, USA). Samples were prepared using continuous
carbon grid method. Grids were nitrocellulose supported 400-mesh copper.
Samples were prepared by applying 3 ml of sample suspension to a cleaned grid,
blotting away with ﬁlter paper, and immediately staining with uranyl formate.
Electron microscopy was performed using an FEI Tecnai T12 electron microscope,
operating at 120 keV equipped with an FEI Eagle 4 k  4 k CCD camera. Negative
stain grids were transferred into the electron microscope using a room temperature
stage. Images of each grid were acquired at multiple scales to assess the overall
distribution of the specimen. After identifying, potentially, suitable target areas for
imaging at lower magniﬁcations, pairs of high magniﬁcation images were acquired
at nominal magniﬁcations of 110,000  (0.10 nm per pixel), 67,000  (0.16 nm per
pixel) and 52,000  (0.21 nm per pixel). The images were acquired at a nominal
underfocus of  2 mm (110,000  ),  3 to  2 mm (67,000  ) and  4 to  3 mm
(52,000  ) and electron doses of B25–45 eÅ  2. A two-dimensional class
averaging was applied to the images. Hereto, individual particles in the 67,000 
or 110,000  high magniﬁcation images were selected using automated picking
protocols29. An initial round of alignments was performed and from that
alignment class averages that appeared to contain real particles were selected for
additional rounds of alignment. A reference-free alignment strategy based on the
X-windows-based microscopy image processing package (Xmipp)30 was applied,
which contains an algorithm that aligns the selected particles and sorts them into
self-similar groups of classes.
Crystallization and structure determination. Crystals were grown by the
vapor-diffusion method in hanging drops at 18 °C by mixing prefusion RSV F
proteins at 4–5 mg ml  1 with a reservoir solution consisting of 1.24–1.34 M K/Na
tartrate, 0.2 M Li2SO4, and 0.1 M CHES pH 9.5. Prior to freezing in liquid nitrogen,
crystals were transferred to a 3.5 M (NH4)2SO4 solution. Initial X-ray diffraction
data were collected remotely at the National Synchrotron Light Source beamline
X6A, and the ﬁnal X-ray diffraction data were collected remotely at a wavelength of
0.9792 Å at the Advanced Photon Source beamline SBC 19ID. Data were processed
with iMOSFLM31 and AIMLESS32, and a molecular replacement solution was
obtained by PHASER33 using the structure of RSV F Cav1 (PDB ID: 4MMR)10 as a
search model. Iterative rounds of model building and reﬁnement were performed
with COOT34 and PHENIX35, respectively. Final data collection and reﬁnement
statistics are presented in Table 1. Ramachandran statistics for the SC-TM and the
PR-DM are 96.0% and 97.5% favoured, 3.8% and 2.0% allowed and 0.2% and 0.5%
outliers, respectively.
Mouse studies. Six to eight-week-old speciﬁc pathogen-free female BALB/c mice
were purchased from Charles River and kept at the institutional animal facility
under speciﬁc pathogen-free conditions. Animals were randomly distributed in
experimental groups of nine animals and were vaccinated intramuscularly in the
gastrocnemius of both hind legs (50 ml per leg) with 0.5 mg of F protein with 50 mg
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of poly(I:C) or 0.5 mg of F protein without adjuvant. All animals received two
injections 4 weeks apart. Serum was obtained by submandibular bleeding or heart
puncture under isoﬂuorane anaesthesia at weeks 0, 4, 6 and 12.
Cotton rat studies. Groups of eight female cotton rats between 6–8 weeks of age
(Sigmovir Biosystems, Inc., Rockville MD) were immunized intramuscularly with
0.5 or 5 mg RSV F with or without AdjuPhos and boosted 28 days later with the
same dose. Animals were challenged at day 49 with RSV A2 with 105 plaque
forming units (p.f.u.) and euthanized at day 54. There was a group of cotton rats
that was injected with buffer only and served as negative control. Serum samples
were collected before prime immunization (day 0), before the boost immunization
(day 28) and before challenge (day 49) for VNA titer measurement by a plaque
reduction assay. Cotton rats were euthanized 5 days after infection, a time point at
which RSV challenge virus reaches peak titers36. Lung and nasal tissue were
isolated and homogenized. RSV load in the tissue homogenates was determined by
virus plaque titration36,37and presented as p.f.u. per gram of tissue.
Virus neutralization assay. VNA in mouse serum was determined by a
microneutralization assay. RSV-susceptible VERO cells (obtained via Berna
Biotech, Bern) were seeded in 96-well cell-culture plates 1 day prior to infection.
On the day of infection, serially diluted sera and controls were mixed with
1,000 p.f.u. of RSV in 96-well U-bottom plates and incubated for 1 h at 37 °C.
Subsequently, virus/antibody mixes were transferred to 96-well plates containing
VERO cell monolayers and transferred to an incubator at 37 °C. Three days later
monolayers were washed and ﬁxed with 80% ice-cold acetone. RSV replication was
determined by F protein expression. Fixed monolayers were incubated with a
biotin-conjugated anti-F monoclonal antibody and washed. Streptavidin-horseradish peroxidase (SA-HRPO) was added to the wells. The wells were washed
again, and turnover of the 3,30 ,5,50 -tetramethylbenzidine substrate was measured at
an optical density of 450 nm (OD450). VNA titers were calculated as the antibody
concentration that caused a 50% reduction in the OD450, expressed as IC50 titers.
VNA for cotton rat serum was determined by a plaque reduction assay. In brief,
heat-inactivated serum samples were diluted 1:10 with Eagle’s minimal essential
medium (Lonza) and serially diluted further 1:4. Diluted serum samples were
incubated with RSV A2 or A/Long (25–50 p.f.u.) for 1 h at room temperature and
inoculated in duplicates onto conﬂuent HEp-2 monolayers in 24-well plates. After
1 h incubation at 37 °C in a 5% CO2 incubator, cells were overlayed with 0.75%
methylcellulose medium (Sigma) and plates were incubated at 37 °C in the
incubator. Four days later the overlay was removed and the cells were ﬁxed with
0.1% crystal violet stain for 1 h, then rinsed and air dried. VNA titers were
expressed as IC50 titers, the antibody concentration that caused a 50% reduction in
the average plaque count of virus-only incubated cells.
Statistical analysis. The results of the VNA titer were log-transformed and
comparisons of prefusion F and postfusion F protein groups (across dose) or
between adjuvanted and non-adjuvanted groups were performed using a
non-parametric Cochran-Mantel-Haenszel test. Comparisons between groups
containing values below the lower limit of quantiﬁcation were analysed using
censored regression models. Wilcoxon Rank-Sum test with Bonferroni correction
for multiple testing was applied when comparing lung titers and nose titers of the
postfusion and prefusion groups, omitting the adjuvanted groups and the PBS
group. The overall level of signiﬁcance (alpha) was set at 5%. All statistical analyses
were performed in SAS version 9.4.
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